Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 17/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.41 |
| ▸ | TDO2 | P48775 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | USP10 | Q14694 | 1/20 | 0.41 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.41 |
| ▸ | USP13 | Q92995 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23572605 | 1.00 | IDO1 (1.00) | IDO1CYP3A4USP2LMNACYP1A2 | |
| SCHEMBL23572591 | 0.90 | IDO1 (1.00) | IDO1CYP3A4LMNACYP1A2CYP2D6 | |
| SCHEMBL29639850 | 0.90 | IDO1 (1.00) | IDO1CYP3A4LMNACYP1A2CYP2D6 | |
| SCHEMBL23572601 | 0.85 | IDO1 (0.74) | IDO1 | |
| SCHEMBL23572600 | 0.76 | IDO1 (0.61) | IDO1CYP2C9 | |
| SCHEMBL23271183 | 0.76 | IDO1 (0.61) | IDO1CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL29639861 | 0.75 | IDO1 (0.60) | IDO1LMNATDO2 | |
| SCHEMBL23271191 | 0.75 | IDO1 (0.60) | IDO1LMNATDO2 | |
| SCHEMBL23572589 | 0.74 | IDO1 (0.61) | IDO1 | |
| SCHEMBL29639837 | 0.74 | IDO1 (0.61) | IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3810116-B1 | NOVEL SUBSTITUTED [1.1.1] BICYCLO COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-11-15 | — | — | EP | disclosed |
| US-11352320-B2 | Substituted [1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2022-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352320-B2 | Substituted [1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors | IDO1, IDO2, TPH1 | IDO1 1/4885CYP3A4 842/4885USP2 2381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.